LTCR-N1-1

N/A

Report date: 2025/01/26 18:31:11

Base Information

Drug NameLTCR-N1-1

Drug Alias Nameautologous EBV specific TCR-redirected T cells (Lion TCR)anti-EBV/HLA class I TCR T-cell therapy (Lion TCR)LTCR-N1-1

ClassificationBiologics > Protein drugs > Recombinant proteinCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy

Mechanisms of ActionHistocompatibility antigens class I modulators

TargetsHistocompatibility antigens class I

Therapy Area/IndicationsNasopharyngeal Carcinoma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritorySingapore

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesLion Tcr Pte Ltd

China Registration ClassN/A

Develop Information

Active CompaniesLion Tcr Pte Ltd

Inactive CompaniesN/A

Active IndicationsNasopharyngeal Carcinoma

Inactive IndicationsN/A

Other Information

ATC CodeN/A